Barely Significant

Excerpts

514,629 sentences

an increasing trendP < 0.0010.0× alphagold
a decreasing trendP < 0.010.2× alphagold
Results The serum levels of 25(OH)D, 25(OH)D3, and F25(OH)D showed a decreasing trend ( z = −2.781–−3.996, P < 0.01) in RA patients with CKD progression from mild to severe, while C3-epi-25(OH)D3 showed an increasing trend ( z = 6.741, P < 0.001) and 25(OH)D2 showed no significant difference among the groups ( z = 0.976, P = 0.329).
highly significantp < 0.0010.0× alphaqualifiedgold
Exploratory analysis led to the observation that participants who obtained COVID-19 vaccine information from such sources also engaged in a higher number of channels for information gathering (median channels = 5 [interquartile range 3,7]) compared to those who did not (median channels = 3 [interquartile range 2,5]) and the difference is highly significant statistically ( Supplementary Table S4 ; p < 0.001).
marginally significantp<0.0010.0× alphagold
In model 1, 2 and 3, the association between hemoglobin (Hb) and diabetic lower extremity ulcers (DLEU) was marginally significant [OR: 0.74, 95% CI: (0.65-0.84); p<0.001] [OR: 0.76, 95% CI: (0.67-0.86); p<0.001] [OR: 0.76, 95% CI: (0.66-0.86); p<0.001], respectively.
highly significantP < 0.0010.0× alphaqualifiedgold
In all the statistical evaluations, P < 0.05 was considered significant difference, P < 0.01 was considered highly significant difference, and P < 0.001 was considered very highly significant difference. 3 Results and discussion 3.1 Preparation and characterization of PPH hydrogel Inspired by catechol-mediated mussel adhesion, we proposed a novel promising strategy for preparation of multifunctional hydrogel.
highly significantP < 0.0010.0× alphaqualifiedgold
The published results showed that, compared with placebo, everolimus showed a highly significant improvement in radiologically defined PFS using both investigator (6.9 vs. 2.8 months, hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.35-0.54; P < 0.001) and independent reviewers’ assessment (10.6 vs. 4.1 months, HR = 0.36; 95% CI, 0.27-0.47; P < 0.001).[ 2 ] Based on these data, the US FDA approved everolimus for the treatment of appropriately selected postmenopausal women with advanced breast cancer.
Progression-free or overall survival…revisited in BOLERO-2.
Indian J Med Paediatr Oncol · 2014 · PMC4080643